You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
AstraZeneca
Colorcon
McKinsey
Baxter

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,796,245

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,796,245 protect, and when does it expire?

Patent 8,796,245 protects XERAVA and is included in one NDA.

This patent has seventy patent family members in thirty countries.

Summary for Patent: 8,796,245
Title:C7-fluoro substituted tetracycline compounds
Abstract: The present invention is directed to a compound represented by Structural Formula (A): ##STR00001## or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
Inventor(s): Zhou; Jingye (Shanghai, CN), Xiao; Xiao-Yi (Lexington, MA), Plamondon; Louis (Montreal, CA), Hunt; Diana Katharine (Cambridge, MA), Clark; Roger B. (Lexington, MA), Zahler; Robert B. (Pennington, NJ)
Assignee: TetraPhase Pharmaceuticals, Inc. (Watertown, MA)
Application Number:13/718,909
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,796,245

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,796,245

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 072990   Start Trial
Argentina 112532   Start Trial
Argentina 112533   Start Trial
Australia 2009279473   Start Trial
Brazil PI0916985   Start Trial
Canada 2732883   Start Trial
China 102177134   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
AstraZeneca
McKesson
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.